Moreau, P., Chari, A., Martínez-López, J., Haenel, M., Touzeau, C., Ailawadhi, S., . . . Goldschmidt, H. (2023). Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: Final analysis of PLEIADES and EQUULEUS.
Citación estilo ChicagoMoreau, Philippe, et al. Daratumumab, Carfilzomib, and Dexamethasone in Relapsed or Refractory Myeloma: Final Analysis of PLEIADES and EQUULEUS. 2023.
Cita MLAMoreau, Philippe, et al. Daratumumab, Carfilzomib, and Dexamethasone in Relapsed or Refractory Myeloma: Final Analysis of PLEIADES and EQUULEUS. 2023.
Precaución: Estas citas no son 100% exactas.